侵袭性肺炎球菌病的长期监测:10价肺炎球菌结合疫苗在巴西萨尔瓦多都会区的影响
该研究在巴西萨尔瓦多都会区9家医院开展2008至2018年前瞻性实验室监测,评估10价肺炎球菌结合疫苗(PCV10)引入前后侵袭性肺炎球菌病(IPD)发病率变化。结果显示总体IPD发病率从引入前2.48/10万降至晚期0.38/10万(IRR 0.15,95%CI 0.09-0.26),≤2岁儿童晚期无病例,≥60岁人群IRR 0.11(95%CI 0.03-0.48)。结论认为PCV10引入后IPD显著下降,包括未接种疫苗的成人,提示直接和间接保护持续至引入后9年,无非疫苗血清型显著替代病证据。
要点
- PCV10引入后晚期(2016-2018)总体IPD发病率降至0.38/10万,较引入前2.48/10万显著下降(IRR 0.15,95%CI 0.09-0.26)。
- 晚期≤2岁儿童无IPD病例,≥60岁人群IRR 0.11(95%CI 0.03-0.48)。
- 晚期PCV10血清型IRR 0.02(95%CI 0.0-0.15),非PCV10血清型IRR 0.27(95%CI 0.14-0.53)。
核心结论
- PCV10引入后IPD显著下降,包括未接种疫苗的成人,提示直接和间接保护持续至引入后9年,无非疫苗血清型显著替代病证据。
- 需持续监测非疫苗血清型变化,为引入更高价PCV的决策提供依据。
研究设计与样本
- 2008至2018年在巴西萨尔瓦多都会区9家医院开展前瞻性实验室监测。
- IPD定义为从正常无菌部位培养出肺炎链球菌,血清型通过多重聚合酶链反应和/或Quellung反应确定。
- 以人口普查数据为分母计算总体、疫苗型和非疫苗型IPD每10万居民发病率,并计算发病率比(IRR)比较引入前(2008-2009)与引入后早期(2010-2012)、中期(2013-2015)和晚期(2016-2018)的发病率。
主要发现
- 引入前所有年龄总体IPD发病率为2.48/10万。
- 引入后早期发病率 initially 升高,IRR 3.80(95%CI 1.18-1.99),晚期降至0.38/10万(IRR 0.15,95%CI 0.09-0.26)。
- 晚期≤2岁儿童无病例(未计算IRR),≥60岁人群IRR 0.11(95%CI 0.03-0.48)。
- 晚期PCV10血清型IRR 0.02(95%CI 0.0-0.15),非PCV10血清型IRR 0.27(95%CI 0.14-0.53)。
- 晚期非PCV10血清型15B、12F、3、17F和19A成为主要血清型,但与引入前相比血清型特异性IPD发病率无显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10) in the national infant immunization program. Limited data on the long-term impact of PCV10 are available from lower-middle-income settings. We examined invasive pneumococcal disease (IPD) in Salvador, Bahia, over 11 years. METHODS: Prospective laboratory-based surveillance for IPD was carried out in 9 hospitals in the metropolitan region of Salvador from 2008 to 2018. IPD was defined as Streptococcus pneumoniae cultured from a normally sterile site. Serotype was determined by multiplex polymerase chain reaction and/or Quellung reaction. Incidence rates per 100,000 inhabitants were calculated for overall, vaccine-type, and non-vaccine-type IPD using census data as the denominator. Incidence rate ratios (IRRs) were calculated to compare rates during the early (2010-2012), intermediate (2013-2015), and late (2016-2018) post-PCV10 periods in comparison to the pre-PCV10 period (2008-2009). RESULTS: Pre-PCV10, overall IPD incidence among all ages was 2.48/100,000. After PCV10 introduction, incidence initially increased (early post-PCV10 IRR 3.80, 95% CI 1.18-1.99) and then declined to 0.38/100,000 late post-PCV10 (IRR 0.15; 95% CI 0.09-0.26). The greatest reductions in the late post-PCV10 period were observed in children aged ≤2 years, with no cases (IRR not calculated) and those ≥60 years (IRR 0.11, 95% CI 0.03-0.48). Late post-PCV10, significant reductions were observed for both PCV10 serotypes (IRR 0.02; 95% CI 0.0-0.15) and non-PCV10 serotypes (IRR 0.27; 95%CI 0.14-0.53). Non-PCV10 serotypes 15B, 12F, 3, 17F, and 19A became predominant late post-PCV10 without a significant increase in serotype-specific IPD incidence compared to pre-PCV10. CONCLUSION: Significant declines in IPD, including among adults not eligible for vaccination, suggest direct and indirect protection up to nine years after PCV10 introduction, without evidence of significant replacement disease. Continued surveillance is needed to monitor changes in non-vaccine serotypes and inform decisions about introducing higher valent PCVs.
引用
- Reis JN, Azevedo J, de Oliveira AML, et al. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil. Vaccine. 2024. PMID: 38184393. doi:10.1016/j.vaccine.2023.12.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。